BBIO vs INSM: fair value comparison
BridgeBio Pharma, Inc. and Insmed Incorporated · Updated 2026-10-19
BBIO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. INSM's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, BBIO currently ranks higher by quality score.
| BBIO | INSM | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $66.39 | $96.27 |
| 12-month range | $53.81–$90.17 | $91.88–$211.41 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #133 of 301 Healthcare | #135 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | — | High |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | Downtrend |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: BBIO fair value analysis · INSM fair value analysis